

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

Assignment ID: PATI509302

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	STA PHARMACEUTICAL HONG KONG LIMITED	10/08/2018
RECEIVING PARTY DATA		
Company Name:	ZENITH EPIGENETICS LTD.	
Street Address:	300,4820 Richard Road SW	
City:	CALGARY	
State/Country:	CANADA	
Postal Code:	T3E 6L1	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	17275465
CORRESPONDENCE DATA		
Fax Number:	6176461666	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	6176461629	
Email:	regional-desk@finnegan.com,amber.bailey@finnegan.com	
Correspondent Name:	Amber Bailey	
Address Line 1:	901 New York Avenue, NW	
Address Line 4:	Washington, DISTRICT OF COLUMBIA 20001	
ATTORNEY DOCKET NUMBER:	12263.0006-00000	
NAME OF SUBMITTER:	Amber Bailey	
SIGNATURE:	Amber Bailey	
DATE SIGNED:	09/20/2024	
Total Attachments: 2		
source=12263.0006 STA Pharma to Zenith#page1.tiff		
source=12263.0006 STA Pharma to Zenith#page2.tiff		

ASSIGNMENT

WHEREAS, STA Pharmaceutical Hong Kong Limited, a corporation of China whose post office address is c/o Shanghai SynTheAll Pharmaceutical Co., Ltd., 9 Yuegong Road West, Shanghai Chemical Park, Shanghai, China 201507, (hereinafter referred to as Assignor) has an interest, by assignment, in an invention entitled:

SOLID FORMS OF A BET BROMODOMAIN INHIBITOR

as disclosed and claimed in the applications identified below this paragraph:

Application Number	Country of Filing	Filing Date
62/730,849	U.S.	09-13-2018

WHEREAS, Zenith Epigenetics Ltd, a corporation of Canada whose post office address is 300, 4820 Richard Road SW, Calgary, AB, Canada, T3E 6L1 (hereinafter referred to as Assignee), is desirous of acquiring the interest previously assigned to Assignor in and to this invention in all countries throughout the world, any and all application(s) for patents in any country on this invention, including any international applications filed under the Patent Cooperation Treaty (PCT) or other multinational agreement and any national stage entry applications in any country based thereon, and any and all Letters Patent to be issued upon such application(s) in any country;

NOW THEREFORE, be it known that, for good and valuable consideration, the receipt of which from Assignee is hereby acknowledged, Assignor hereby sells, assigns, transfers, and sets over unto the Assignee, its lawful successors and assigns, its entire right, title, and interest in and to this invention in all countries throughout the world, all application(s) for patents in any country, including any provisional applications, non-provisional applications, and continuation, divisional, or continuation-in-part applications that disclose the invention, any international applications filed under the Patent Cooperation Treaty (PCT) or other multinational agreement and any national stage entry applications in any country based thereon, and any and all Letters Patent, utility model patents, and certificates of invention to be issued upon such filed application(s) in any country and any extensions, restorations, renewals, or reissues thereof;

AND, Assignor further covenants and agrees that it will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or by said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

AND, Assignor HEREBY covenants that it has the full right to convey the interest assigned by this Assignment, and Assignor has not executed and will not execute any agreement in conflict with this Assignment.

IN TESTIMONY WHEREOF, Assignor has executed this Assignment by its duly authorized representative, effective as of the date written below.

ASSIGNOR

STA Pharmaceutical Hong Kong Limited

X. S. Wen

Signature

Xianghui Wen

Print Name

Vice President

Corporate Title

Oct. 08, 2018

Execution Date

ACKNOWLEDGED BY:

Zenith Epigenetics Ltd.

HCH

Signature

Henrik C. Hansen

Print Name

Senior Vice President, Operations

Corporate Title

OCT. 9/ 2018

Execution Date